Blockade Medical has received CE mark for its Barricade Coil System which is designed to occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.
“The use of platinum microcoils to treat intracranial aneurysms will continue to expand the neurovascular market. Coil embolization is the standard of care and is proven to be safe and effective for both ruptured and unruptured aneurysms. It is because of this safety and efficacy record that coil embolization will remain the standard of care in aneurysm treatment for years to come. The Barricade Coil System is our first product offering, which Blockade plans to complement with additional products in 2013,” said Gibb Clarke, CEO, Blockade Medical.
“From my initial experience, the Barricade Coil System offered competitive performance in terms of deliverability, aneurysm conformability, filling and finishing. The framing coil allows me to frame and fill the aneurysm effectively while delivering coils without sacrificing catheter position. The system also offers long filling and soft finishing coils to enable complete aneurysm embolization,” said Raymond Turner, endovascular neurosurgeon, Medical University of South Carolina, Charleston, South Carolina, USA, and Blockade Medical’s clinical advisor.
The company believes the Barricade Coil System line of embolization coils will allow physicians and hospitals to safely and efficiently provide therapeutic options for treating cerebral aneurysms. The Barricade Coil System is approved in 10 and 18 framing, filling and finishing coil configurations.
